GlassScriptPhysician profile
Aisha Siddiqa
NPI 1881145837
$3,728.61
in general payments reported to CMS, 2019-2025
16 companies · $1,407 in 2025
The $1,407 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.52 · 2022: $160 · 2023: $913 · 2024: $1,234 · 2025: $1,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,527 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,526.96 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $623.33 | 2023-2025 | Invega Sustenna, Spravato |
| Lundbeck LLC | $537.74 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $473.86 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $301.43 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $300.48 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $223.06 | 2022-2024 | Trintellix |
| Alkermes, INC. | $215.48 | 2022-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $204.08 | 2023-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Abbvie INC. | $184.76 | 2023-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $173.76 | 2023-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $129.74 | 2023-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $127.38 | 2024-2025 | Fanapt, Hetlioz |
| Indivior INC. | $102.80 | 2023-2024 | Perseris, Sublocade |
| Neurocrine Biosciences, INC. | $74.91 | 2024-2025 | Ingrezza |
| Tris Pharma INC | $33.06 | 2024-2025 | Onyda Xr, Dyanavel Xr |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $22.74 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aisha Siddiqa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.